Potential Therapeutic Drugs and Methods for the Treatment of Amyotrophic Lateral Sclerosis

Author(s): G. Yacila, Y. Sari.

Journal Name: Current Medicinal Chemistry

Volume 21 , Issue 31 , 2014

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Abstract:

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder caused by damage of motoneurons leading to paralysis state and long term disability. Riluzole is currently the only FDA-approved drug for the treatment of ALS. The proposed mechanisms of ALS include glutamate excitotoxicity, oxidative stress, mitochondrial dysfunction, protein aggregation, SOD1 accumulations, and neuronal death. In this review, we discuss potential biomarkers for the identification of patients with ALS. We further emphasize potential therapy involving the uses of neurotrophic factors such as IGFI, GDNF, VEGF, ADNF-9, colivelin and angiogenin in the treatment of ALS. Moreover, we described several existing drugs such as talampanel, ceftriaxone, pramipexole, dexpramipexole and arimoclomol potential compounds for the treatment of ALS. Interestingly, the uses of stem cell therapy and immunotherapy are promising for the treatment of ALS.

Keywords: ALS, ADNF-9, biomarkers, ceftriaxone, colivelin, neurotrophic factor, neurodegenerative disease, stem cell.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 21
ISSUE: 31
Year: 2014
Page: [3583 - 3593]
Pages: 11
DOI: 10.2174/0929867321666140601162710
Price: $58

Article Metrics

PDF: 42